Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics

Acta Academiae Medicinae Sinicae

Volumn 29, Issue 6, 2007, Pages 719-724

  Yuan, Kai Long ^a   Shi, Xian Zhe ^a   Lu, Xin ^a   Gao, Peng ^a   Xu, Guo Wang ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

Diabetes mellitus; Gas chromatography; Losartan; Metabonomics; Therapeutic effect

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; BIOLOGICAL MARKER; CREATININE; INOSITOL; LOSARTAN; SORBITOL;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; METABOLOMICS; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; URINALYSIS;

ALBUMINURIA; BIOLOGICAL MARKERS; CHROMATOGRAPHY, GAS; CREATININE; DEOXYGUANOSINE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; LOSARTAN; METABOLOME; SORBITOL;

EID: 38849126198     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Nicholson JK, Lindon JC, Holmes E. Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data [J]. Xenobiotica, 1999, 29(11):1181-1189.
2. Jiye A, Trygg J, Gullberg J, et al. Extraction and GC/MS analysis of the human blood plasma metabolome [J]. Anal Chem, 2005, 77(24):8086-8094.
3. Lindon JC, Holmes E, Nicholson JK. So what's the deal with metabonomics [J]? Anal Chem, 2003, 75(17): 384A-391A.
4. Lindon JC, Holmes E, Nicholson JK. Metabonomics techniques and applications to pharmaceutical research & development [J]. Pharm Res, 2006, 23(6):1075-1088.
5. Lindon JC, Nicholson JK, Holmes E, et al. Metabonomics: metabolic processes studied by NMR spectroscopy of biofluids [J]. Concepts Magn Reson, 2000, 12(2):289-320.
6. Griffin JL. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis [J]. Curr Opin Chem Biol, 2003, 7(5):648-654.
7. Nicholson JK, Wilson ID. Understanding 'global' systems biology: metabonomics and the continuum of metabolism [J]. Nat Rev Drug Discov, 2003, 2(8):668-676.
8. Kussmann M, Raymond F, Affolter M. OMICS-driven biomarker discovery in nutrition and health [J]. J Biotechnol, 2006, 124(4):758-787.
9. Anthony ML, Sweatman BC, Beddll CR, et al. Pattern recognition of the sit of nephrotoxicity based on metabolic data derived from proton nuclear magnetic resonance spectra of urine [J]. Mol Pharmacol, 1994, 46(1):199-121.
10. Holmes E, Nicholson JK, Nicholls AW, et al. The identification of novel biomarkers of renal toxicity using automatic data reduction techniques and PCA of proton NMR spectra of urine [J]. Chemometr Intell Lab, 1998, 44:245-255.
11. Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetic mellitus: a review of the clinical trial evidence [J]. Clin Ther, 2003, 25 (12):3044-3064.
12. Wiwanitkit V. Glucosuria and albuminuria in diabetic nephropathy: a consideration at nanolevel [J]. J Diabetes Complications, 2007, 21(3):164-165.
13. Chinese source.
14. Wong PC, Chin AT. The preclinical basis of therapeutic evaluation of losartan [J]. J Hypertens, 1995, 13 (Suppl 1):1-4.
15. De ZD, Gansevoort RT, De JPE. Losartan in patients with renel insufficiency [J]. Can J Cardiol, 1995, 11(11):41-44.
16. Mei SR, Yao QH, Xu GW, et al. Capillary electrophoresis with end-column amperometric detection of urinary 8-hydrox-y-2′-deoxyguanosine [J]. Electrophoresis, 2003, 24(9): 1411-1415.
17. Xu GW, Yao QH, Weng QF. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic mellitus nephropathy patients [J]. J Pharm Biomed Anal, 2004, 36(1):101-104.
18. Yuan KL, Kong HW, Xu GW. A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile [J]. J Chromatogra B, 2007, 850(1-2):236-240.
19. Wohl P, Krušinová E, Klementová M. et al. Urinary urea mtrogen excretion during the hyperinsulinemic euglycemic clamp in type 1 diabetes patients and healthy subjects [J/OL]. Physiol Res, 2007, [2007-07-30]. http://www.ncbi.nlm.nih.gov/sites/ entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch= 17552877&ordinalpos=2&itool= EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum.
20. Guirguis AF, Taylor HC. Nephrogenic diabetes insipidus persisting 57 months after cessation of lithium carbonate therapy: report of a case and review of the literature [J]. Endocr Pract, 2000, 6(4):324-328.
21. Eckfelde JH, Leindecker FC, Kershaw MJ. Calibration of 3-hydroxybutyrate assays [J]. Clin Chem, 1984, 30(6): 1116-1118.
22. Dolink V, Bocek P. Determination of pyrutate, lactate, acetoacetate and β-hydroxybutyrate in serum by capillary isotachophoresis [J]. J Chromatogr, 1981, 225(2):455-458.
23. Tharandt L, Hübner W, Hollmann S. Investigations on the utilization of D-gluconate and D-glucono-delta-lactone in the metabolism of the normal and alloxan diabetic rat (author's transl) [J]. J Clin Chem Clin Biochem, 1979, 17(4): 257-267.
24. Chinese source.
25. Breyer JA, Hunsicker LG, Bain RP. Angiotensim converting enzyme inhibitor in diabetic nephropathy [J]. J Kidney Int, 1994, 45(Suppl 1):156-160.